Celerion
Lincoln, Nebraska, 68502, United States
NCT Number: NCT02954263
Multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TD-1439 in healthy adult and elderly subjects
Looking for future studies?
Notify Me19 year–80 year
All sexes
Interventional
Phase 1
Lincoln, Nebraska, 68502, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From Day 1 through end of study (Day 25)
Time frame: Day 1 to 3 days after last dose (Day 17)
Time frame: Day 1 to 3 days after last dose (Day 17)
Time frame: Day 1 to 3 days after last dose (Day 17)
Time frame: Day 1 to 3 days after last dose (Day 17)
Time frame: Day 1 to 3 days after last dose (Day 17)
Time frame: Day 1 to 3 days after last dose (Day 17)
Time frame: Day 1 to 3 days after last dose (Day 17)
Time frame: Day 1 to 3 days after last dose (Day 17)
Time frame: Day 1 to 3 days after last dose (Day 17)
Time frame: Day 1 to 3 days after last dose (Day 17)
Time frame: Day 1 to 3 days after last dose (Day 17)
Time frame: The day before dosing (Day -1) to 3 days after last dose (Day 17)
Time frame: The day before dosing (Day -1) to 3 days after last dose (Day 17)
Time frame: The day before dosing (Day -1) to 3 days after last dose (Day 17)
Theravance Biopharma
Industry
A Phase 1, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD-1439 in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02709928
Healthy Adults, Elderly Subjects
Lincoln, Nebraska, United States
View Trial Details